- Home
- IDYA vs ACLS Comparison
IDYA vs ACLS Comparison
Compare IDYA & ACLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- ACLS
- Stock Information
- Founded
- IDYA 2015
- ACLS 1995
- Country
- IDYA United States
- ACLS United States
- Employees
- IDYA N/A
- ACLS N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- ACLS Industrial Machinery/Components
- Sector
- IDYA Health Care
- ACLS Technology
- Exchange
- IDYA Nasdaq
- ACLS Nasdaq
- Market Cap
- IDYA 2.3B
- ACLS 2.6B
- IPO Year
- IDYA 2019
- ACLS 2000
- Fundamental
- Price
- IDYA $32.18
- ACLS $83.14
- Analyst Decision
- IDYA Buy
- ACLS Buy
- Analyst Count
- IDYA 17
- ACLS 7
- Target Price
- IDYA $48.20
- ACLS $97.00
- AVG Volume (30 Days)
- IDYA 1.3M
- ACLS 675.1K
- Earning Date
- IDYA 11-04-2025
- ACLS 11-04-2025
- Dividend Yield
- IDYA N/A
- ACLS N/A
- EPS Growth
- IDYA N/A
- ACLS N/A
- EPS
- IDYA N/A
- ACLS 4.91
- Revenue
- IDYA $7,000,000.00
- ACLS $896,089,000.00
- Revenue This Year
- IDYA $90.17
- ACLS N/A
- Revenue Next Year
- IDYA $219.42
- ACLS $5.53
- P/E Ratio
- IDYA N/A
- ACLS $16.94
- Revenue Growth
- IDYA N/A
- ACLS N/A
- 52 Week Low
- IDYA $13.45
- ACLS $40.40
- 52 Week High
- IDYA $33.64
- ACLS $102.93
- Technical
- Relative Strength Index (RSI)
- IDYA 67.18
- ACLS 45.49
- Support Level
- IDYA $28.17
- ACLS $81.96
- Resistance Level
- IDYA $33.64
- ACLS $85.53
- Average True Range (ATR)
- IDYA 1.68
- ACLS 3.01
- MACD
- IDYA 0.40
- ACLS -0.11
- Stochastic Oscillator
- IDYA 80.76
- ACLS 56.00
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About ACLS Axcelis Technologies Inc.
Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.